---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-25-000030"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T08:07:19.153375+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Akebia shareholders approve 18.9M share increase to 2023 Stock Incentive Plan

## Summary
- Shareholders approved amendment to 2023 Stock Incentive Plan to increase shares by 18,900,000 (102.75M for, 48.21M against).
- Directors John P. Butler and Myles Wolf re-elected as Class II directors with over 119.9M votes each.
- Advisory vote on executive compensation passed with 110.68M for, 39.01M against.
- Ratification of Ernst & Young as auditor for 2025 passed with 178.59M for, 8.90M against.

## SEC filing metadata
- accession: 0001517022-25-000030
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000030/0001517022-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000030/akba-20250610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-25-000030
- JSON: https://secwatch.observer/filing/0001517022-25-000030.json
- Plain text: https://secwatch.observer/filing/0001517022-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.